Exposure of multiple myeloma-bearing immunodeficient mice to γ-secretase inhibitors augmented BCMA expression on malignant cells, reduced the presence of soluble BCMA, and promoted the antitumor activity of BCMA-specific CAR-T cells [25]. Here, TNFRSF17 is linked to plasma cell myeloma.